Forgot password?

The Fondation Brocher is an essential player in this vital thinking process: one which will help make us aware of the real challenges in using our resources for maximum impact on the health of the people of the world.



Professor Daniel Wikler, Harvard University


The Brocher Foundation is a Swiss non-profit private foundation  recognized of public interest. Your donations are tax deductible according to the regulations in force.


October 9 - 11, 2019

When drug companies become doctors: consequences and responses


An Examination of the Ethical, Legal and Social Implications of the WTO TRIPS Agreement on access to gene and cell-based treatments including CAR T and CRISPR

Tuesday, 8 October 2019

19:30 Welcome Reception and Dinner (for 21 participants staying at the Brocher Foundation)

Keynote speeches - Jamie Love and Ellen ‘t Hoen

Wednesday, 9 October 2019

9:00 - 9:10: Welcome and introduction - Thiru Balasubramaniam

Science and Technology - An overview of cell and gene based treatments

9:10 - 10:10 Chimeric antigen receptor T cells (CAR T)
Speakers:Diane Singhroy, Paul Fehlner, Roman Macaya

10:10 - 11:10 - Discussion moderated by Dr. Mariangela Simao
Discussants: Esther van Zimmeren, James Love, Jessica Burry

11:10 - 12:00 Clustered regularly interspaced short palindromic repeats (CRISPR)
Speakers: Hannes Braberg, Diane Singhroy

12:00 - 13:00 Discussion moderated by Dr. Marie-Paule Kieny
Discussants: Soumya Swaminathan, Julian Cockbain, Robert Watson

13:00 - 14:00 Lunch

Exploring challenges and solutions to pricing, access and manufacturing cell and gene-based treatments

14:00 - 15:00 Manufacturing
Speakers: Paul Fehlner, Roman Macaya

15:00 - 16:00 Pricing and Access
Speakers: James Love, Gaelle Krikorian, Marcel Van Raaij, Irene Bernal

16:00 - 16:30 Coffee break

16:30 - 18:00 Discussion on challenges and solutions to pricing, access and manufacturing cell and gene-based treatments moderated by Charles Gore
Discussants: Ellen ‘t Hoen, Richard Sullivan, Luca Li Bassi, Vincenzo Pavone

19:30 Dinner

Thursday, 10 October 2019

Legal and Regulatory barriers to providing access to cell and gene-based treatments

9:00 - 10:30 - Legal questions
Speakers: James Love, Ellen ‘t Hoen, Esther van Zimmeren, Carlos Correa

10:30 - 11:00 Coffee break

11:00 - 12:00 Discussion moderated by Thiru Balasubramaniam

12:00 - 13:30 Lunch and Group Photo

13:30 - 15:00 Regulatory questions
Speakers: Luca Li Bassi, Mariangela Simao, Marcel Van Raaij

15:00 - 16:00 Discussion moderated by Yannis Natsis

16:00 - 16:30 Coffee break

16:30 - 18:00 Normative solutions - Discussion moderated by Ellen ‘t Hoen

19:30 Dinner

Friday, 11 October 2019

Report writing


Brocher Foundation


This workshop will bring together biomedical, legal, trade, human rights, and public health experts to examine the implications of Article 27.3(a) of the WTO TRIPS Agreement on the patentability of gene and cell-based therapies including those involving CAR T, CRISPR and other technologies when treatment can be described as a service or a medical procedure, rather than a product. The workshop will explore if certain gene and cell-based treatments are, in fact, exempt from patentability when a country has an exception that mirrors Article 27.3(a) of the TRIPS Agreement. Experts will also discuss non-patent approaches to providing incentives to invest in innovations that delink R&D costs from prices and monopolies on the medical technologies for such treatments, for example innovation inducement prize funds and market entry rewards.